AptarGroup, Inc.
- Open
- 131.73
- Day high
- 132.26
- Day low
- 129.77
- Prev close
- 130.92
- Volume
- 472K
- Mkt cap
- $8.3B
- P/E (TTM)
- 23.3
- EPS (TTM)
- $5.60
- P/B
- 3.2
- P/S
- 2.1
- Yield
- 1.47%
- Per share
- $1.92
- ▼Insiders net selling -$4.1M over the last 3 months (0 open-market buys, 8 sales)
- 🏛Institutions accumulating (13F)
AptarGroup, Inc. (ATR) is a Healthcare company listed on NYSE. The stock is down 3% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 8 sales (SEC Form 4). Drillr has 1 published research article covering ATR.
AptarGroup, Inc. (ATR) financials & analyst ratings
Fundamentals (TTM)
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
ATR earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Jul 31, 2026 | $1.36 | $1.42 | +4.6% | $1.0B | +1.5% |
| May 1, 2026 | $1.15 | $1.19 | +3.4% | $983M | +2.9% |
| Feb 5, 2026 | $1.25 | $1.25 | +0.1% | $963M | +4.5% |
| Oct 30, 2025 | $1.57 | $1.62 | +3.1% | $961M | +8.9% |
| Jul 31, 2025 | $1.58 | $1.66 | +5.2% | $966M | +1.0% |
| May 1, 2025 | $1.17 | $1.20 | +2.8% | $887M | -1.5% |
| Feb 6, 2025 | $1.28 | $1.52 | +18.5% | $848M | -0.6% |
| Oct 24, 2024 | $1.43 | $1.49 | +4.4% | $909M | +5.0% |
| Jul 25, 2024 | $1.37 | $1.37 | +0.3% | $910M | -2.6% |
| Apr 25, 2024 | $1.15 | $1.26 | +9.5% | $915M | -1.6% |
| Feb 8, 2024 | $1.12 | $1.21 | +8.1% | $838M | -5.8% |
| Oct 25, 2023 | $1.26 | $1.39 | +9.9% | $893M | -1.4% |
ATR insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 2, 2026 | Touya Gaeldirector, officer: President and CEO | Grant | 9,531 | $130.92 |
| Sep 2, 2026 | Touya Gaeldirector, officer: President and CEO | Grant | 2,637 | — |
| Aug 28, 2026 | Touya Gaelofficer: Segment Pres., CEO Designate | Sell | 325 | $134.55 |
| Aug 28, 2026 | Touya Gaelofficer: Segment Pres., CEO Designate | Sell | 3,415 | $133.69 |
| Aug 5, 2026 | Prieur Marcofficer: Segment President | Sell | 124 | $137.10 |
| Aug 5, 2026 | Prieur Marcofficer: Segment President | Sell | 3,376 | $136.23 |
| Aug 4, 2026 | Tanda Stephan B.director, officer: President and CEO | Sell | 9,838 | $136.16 |
| Aug 4, 2026 | Tanda Stephan B.director, officer: President and CEO | Option | 9,838 | $74.79 |
| Aug 3, 2026 | Tlili Hediofficer: Segment President | Sell | 8,854 | $135.00 |
| Jul 17, 2026 | Wunderlich Ralf K.director | Grant | 151 | — |
| Jul 17, 2026 | FOTIADES GEORGE Ldirector | Grant | 151 | — |
| Jul 17, 2026 | Trerotola Matthew L.director | Grant | 151 | — |
| Jul 17, 2026 | Matthews Candace S.director | Grant | 226 | — |
| Jul 17, 2026 | Marey-Semper Isabeldirector | Grant | 151 | — |
| Jul 17, 2026 | Owens B Craigdirector | Grant | 151 | — |
Source: ATR SEC Form 4 filings, latest Sep 2, 2026. For informational purposes only — not investment advice.
See the full ATR insider & 13F page →AptarGroup, Inc. company profile
Overview
AptarGroup, Inc. (NYSE:ATR) is a global leader in dispensing, sealing, and material science solutions founded in 1992 and incorporated in Delaware. The company went public in April 1993 and is headquartered in Crystal Lake, Illinois. AptarGroup serves diverse markets including pharmaceuticals, beauty and personal care, home care, and food and beverage industries through its three main business segments. The company has established itself as a critical supplier of specialized packaging components and drug delivery systems, with a particular strength in pharmaceutical applications where it has built significant competitive advantages through proprietary technologies and regulatory expertise.
Business
AptarGroup operates in the specialized packaging and dispensing systems industry, manufacturing components that enable the safe and effective delivery of products ranging from prescription medications to cosmetics and food products. The company's core business revolves around creating sophisticated dispensing mechanisms, sealing solutions, and advanced material science applications. The company operates through three primary segments. Pharma represents the largest and most profitable segment, generating approximately 35% EBITDA margins. This division produces metered dose inhaler valves for respiratory treatments like asthma medications, nasal spray pumps for allergy treatments, elastomeric components for injectable drug packaging (including high-value GLP-1 diabetes medications), and active material science solutions that can enhance drug stability and delivery. The Pharma segment has consistently delivered strong growth, with core sales increasing 7-10% annually. Beauty + Home focuses on dispensing solutions for the cosmetics and personal care markets. This segment manufactures pumps for fragrance bottles, dispensers for skincare products, aerosol valves, and closures for personal care and home cleaning products. While this segment faces more cyclical demand patterns tied to consumer discretionary spending, it benefits from the premiumization trend in beauty products and the growing home care market. Food + Beverage (also called Closures) produces dispensing and non-dispensing closures, spray pumps, and aerosol valves for food and beverage applications. This segment serves both functional needs (like condiment dispensers) and convenience applications (such as beverage closures with pour spouts). The segment has returned to its long-term target growth range after facing challenges from resin cost fluctuations. The pharmaceutical segment represents the company's highest-growth and highest-margin business, while Beauty + Home and Food + Beverage provide diversification and steady cash flow generation across different economic cycles.
Revenue model
AptarGroup generates revenue primarily through product sales of its manufactured dispensing and packaging components. The company operates on a business-to-business model, selling directly to pharmaceutical companies, beauty brands, personal care manufacturers, and food and beverage producers. Revenue is generated when customers purchase AptarGroup's components to incorporate into their final products. The company's customers include major pharmaceutical companies developing drug delivery systems, prestige beauty brands requiring premium dispensing solutions, consumer goods companies needing reliable packaging components, and food and beverage manufacturers seeking functional closure systems. The pharmaceutical segment commands premium pricing due to the specialized nature of drug delivery systems and the extensive regulatory requirements involved. Several factors influence AptarGroup's profitability margins. Positive margin drivers include the company's focus on proprietary drug delivery systems in pharmaceuticals, which command higher margins due to their specialized nature and regulatory barriers. The growing demand for injectable medications, particularly GLP-1 diabetes drugs, provides strong pricing power. Additionally, the company's "local-for-region" manufacturing strategy helps mitigate transportation costs and currency fluctuations while providing supply chain resilience. Margin pressures come from raw material cost inflation, particularly for specialized polymers and elastomers used in pharmaceutical applications. Currency fluctuations affect international operations, though the local manufacturing strategy provides some natural hedging. Competitive pricing pressure exists in the more commoditized beauty and food & beverage segments. The company also faces periodic destocking cycles, particularly in consumer healthcare products like cold and flu treatments, which can create temporary volume declines. Economic downturns can reduce demand for discretionary beauty products, while pharmaceutical demand remains more resilient due to the essential nature of medications.
Competitive moat
AptarGroup possesses a moderate to strong competitive moat, particularly in its pharmaceutical segment. The company's primary moat stems from its specialized expertise in drug delivery systems and the significant regulatory barriers that protect its market position. In pharmaceuticals, AptarGroup's components must meet stringent FDA and international regulatory standards, creating high switching costs for customers who have already validated specific delivery systems for their drugs. The company's proprietary technologies, such as its nasal delivery platforms and specialized elastomeric formulations for injectables, provide additional protection through intellectual property. The company benefits from high customer switching costs in pharmaceuticals, where changing suppliers requires extensive revalidation studies that can take years and cost millions of dollars. This creates sticky customer relationships and recurring revenue streams. AptarGroup's "local-for-region" manufacturing strategy with 11 plants in North America and facilities worldwide provides supply chain advantages and reduces customers' supply risk concerns. However, the moat is weaker in beauty and food & beverage segments, where products are more commoditized and switching costs are lower. Competition from lower-cost manufacturers, particularly in Asia, poses ongoing challenges. The beauty segment faces particular pressure from changing consumer preferences and the rise of direct-to-consumer brands that may prioritize cost over premium packaging solutions. Potential disruption could come from new drug delivery technologies, such as oral alternatives to injectable medications (like oral GLP-1 pills), though management believes auto-injectors will remain important even as oral options emerge. Additionally, 3D printing and other manufacturing innovations could potentially lower barriers to entry in some product categories. The company's sustainability initiatives and partnerships with recycling technology companies represent both defensive moves against environmental regulations and potential sources of future competitive advantage.
Risks & safety
AptarGroup demonstrates solid financial stability with manageable debt levels and consistent cash generation, though trading at elevated valuation multiples. • Liquidity and Debt: Strong balance sheet with $126 million cash, current ratio of 1.25, and debt-to-equity ratio of 0.41. No immediate solvency concerns with consistent positive free cash flow generation. • Cash Generation: Positive free cash flow of $26 million in Q1 2025, though down from stronger prior periods. Full-year 2024 generated $367 million in free cash flow, demonstrating underlying cash generation capability. • Valuation Metrics: Trading at premium multiples - P/E ratio of 31.2x, EV/EBITDA of 14.7x, and price-to-book of 3.9x. These metrics suggest limited margin of safety at current prices. • Profitability: ROE of 3.1% appears low but reflects quarterly timing; full-year 2024 ROE was 15.2%, indicating solid underlying profitability. • Other Considerations: Dividend-paying company with consistent increases, share buyback program active, and diversified end markets provide some downside protection. However, exposure to cyclical beauty and consumer discretionary spending creates some earnings volatility risk.
Recent development
Over the past few years, AptarGroup has executed several strategic initiatives to strengthen its market position and drive growth. The company underwent a significant organizational realignment in 2023, restructuring its segments to be closer to customers and improve operational efficiency. This included establishing clearer segment focus with Aptar Pharma, Aptar Beauty, and Aptar Closures. In pharmaceuticals, AptarGroup has aggressively expanded its proprietary drug delivery capabilities. Key developments include the FDA approval and market launch of nasal epinephrine (neffy), acquisition of SipNose technology assets for intranasal delivery platforms, and entering an agreement for Cambridge Healthcare Innovations' dry powder inhaler platform. The company has also developed specialized elastomeric components for high-value GLP-1 injectable medications and expanded its active material science solutions, which grew 35% in Q4 2024. The company has strengthened its digital health initiatives through partnerships with Biogen for the Cleo digital therapeutic platform and continued development of its Migraine Buddy application. AptarGroup was also awarded a U.S. government contract for its ActivShield sterilization technology, and its N-Sorb technology was accepted into the FDA's Emerging Technology Program. Sustainability and innovation investments have been significant focus areas. The company achieved EcoVadis Platinum rating (top 1% of 150,000 companies) and was named to Barron's most sustainable U.S. companies list for seven consecutive years. AptarGroup has formed strategic partnerships with PureCycle Technologies for ultra-pure recycled polypropylene applications and continues developing recyclable packaging solutions. Manufacturing and operational improvements include capacity expansion in injectables, improved plant utilization (over 12% improvement in closures segment), and continued cost reduction efforts across all segments. The company has also been selective in bolt-on acquisitions to add capabilities and geographic reach while maintaining financial discipline.
ATR company profile · for informational purposes only — not investment advice.
Track ATR with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free